COMP <GO>
ZLAB vs SUPN // DIVIDEND YIELD & FCF PAYOUT SAFETY
Zai Lab Limited (NASDAQ) VS. Supernus Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: ZLAB 2
— SUPN 8
■ METRIC PARITY
LAST: $21.67 (-1.83%) • MKT CAP: $2.48B
dividend-safety
0.00%
LAST: $41.92 (+0.19%) • MKT CAP: $2.44B
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ZLAB VS. SUPN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ZLAB | SUPN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 58.30% | 89.60% | -31.30 | SUPN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -4.50% | -30.50 | SUPN | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.33% | 1.89% | -8.22 | SUPN | /fcf-yield <GO> |
| Operating Margin | -50.20% | -8.70% | -41.50 | SUPN | /operating-margins <GO> |
| Net Profit Margin | -38.40% | -5.40% | -33.00 | SUPN | /net-margins <GO> |
| Revenue Growth (YoY) | 15.00% | 8.60% | +6.40 | ZLAB | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.52 | 4.84 | -4.32 | SUPN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | SUPN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.8 | 51.1 | -10.30 | SUPN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.88 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 22.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.48B | $2.44B | $36.5M | ZLAB | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ZLAB REV | SUPN REV | ZLAB GROSS % | SUPN GROSS % | ZLAB FCF | SUPN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $457.2M | $719.0M | 58.3% | 89.6% | -$158.9M | $46.0M |
| FY 2024 | $397.6M | $661.8M | 63.0% | 88.2% | -$220.5M | $171.2M |
| FY 2023 | $266.7M | $607.5M | — | — | -$198.2M | $83.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ZLAB // BETA —
SUPN // BETA 0.88